Tactile Systems Technology, Inc. (TCMD) Earnings Call Transcript
May 4, 2026
Earnings Call Speaker Segments
Good afternoon, and thanks for being on today's call. Joining me from the management team at Tactile Systems Technology, Inc. are Sheri Louise Dodd, our Chief Executive, along with Elaine M. Birkemeyer, who serves as Chief Financial Officer. Prior to starting, I want to remind all of you that what we say and how we answer your questions today might include forward-looking statements. Those are based on what management currently expects and carry inherent risks and uncertainties. As a result, actual results could differ materially from what those statements indicate, including the risks described in the risk factors section of our Annual Report on Form 10-Ks and in our latest 10-Q filing that will be submitted to the Securities and Exchange Commission. Those factors might be updated periodically in our SEC filings, which you can find on our website. We take on no obligation to publicly update or revise any forward-looking statements because of new information, future events, or otherwise. This call will also reference certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We typically call these non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP can be found in the earnings press release on the Investor Relations portion of our website. With that, I'll hand the call over to Sheri.
Appreciate it, Sam. Hello, everyone, and thanks for joining our Q1 2026 earnings call this afternoon. With me is Elaine M. Birkemeyer, who serves as our Chief Financial Officer. We're pleased to report that 2026 has begun on a strong note, as our Q1 results reflect a disciplined focus on our three strategic priorities, continued resilience and momentum in our commercial action plan, and operational excellence — including preparations for the recent changes involving prior authorization now being introduced for fee-for-service patients. Specifically, in Q1 our total revenue came to $75.3 million, representing 23% growth versus the same quarter last year. Turning to our business lines, lymphedema revenue increased 23% year over year, reaching $62.2 million, while airway clearance revenue grew 22% year over year, arriving at $13.0 million. Q1 results include only a minimal contribution from Lymphotech, which we acquired not long ago. Our revenue figures reflect the ongoing strategy and execution behind the key drivers of revenue: our phased investments in technology and people for go-to-market, which drive referrals and market share; tailwinds related to the NCD, which drive a favorable mix of advanced pump products; the depth and breadth of our DME relationships, which drive market expansion and share; and — this shouldn't be underestimated — disciplined operational execution across the entire enterprise. Beyond that, top-line strength delivered meaningful margin expansion, with gross margins rising 250 basis points to 76.5%, and adjusted EBITDA increasing $4 million year over year to $3.7 million. We ended the first quarter with approximately $75 million in cash, preserving substantial financial flexibility as we continue investing for long-term growth; for 2026, we are revising our full-year revenue guidance to a range of $360 million to $368 million. This revision reflects the addition of Lymphotech as well as our increased confidence in commercial execution, while we remain disciplined as prior authorization outcomes under new Medicare requirements for our category continue to mature; for the remainder of the call, I'll walk through our Q1 performance by business line and then provide updates on the strategic priorities we're pursuing. Elaine will then review our first quarter financial results and update our 2026 outlook. Beginning with lymphedema. Revenue rose 23% year over year in Q1. We're pleased to see such substantial growth compared with last year, which was expected given the momentum behind execution of our field and back-office strategy. The investments we've made in go-to-market are delivering results. Our sales organization now has full resourcing, broad geographic coverage, and a well-balanced staffing model of one account manager for every product specialist. With those resources now in place, our focus is shifting away from capacity investment and onboarding toward productivity and operating leverage. Territory productivity increased meaningfully in Q1 compared with a year ago. Better use of CRM, plus continuous improvements like tools for workflows, is increasingly helping us prioritize referral management and account development, and over time we expect further territory optimization and lasting productivity gains. When it comes to products, lymphedema growth for the quarter as a whole was driven by both Nimble and Flexitouch, and Flexitouch grew at a quicker pace than Nimble. That pattern, as we anticipated, was largely tied to the decision we made in October 2025 to bring our advanced pump documentation criteria into line with the Medicare NCD. Even though aligning was always our plan, the timing we picked reflected greater confidence on our part that MACs were applying the NCD consistently. What really matters is that, compared with the prior LCD policy, the NCD created a path that is simpler and more aligned with clinical practice for patients who require advanced pump therapy. As we continue educating providers about the revised policy and encouraging the notion of pairing the right pump with the right patient, Flexitouch will keep gaining from this favorable momentum. One more important point: the NCD policy's language allows coverage of advanced pumps for people with head and neck lymphedema, and it pleases us to see rising clinical adoption among these underserved patients, who otherwise lack any pneumatic or nonpneumatic compression device options whatsoever. Flexitouch's strength driven by the NCD was also evident in our Q1 payer mix, with sales via our Medicare channel rising 40% versus the year-earlier period. To a smaller extent, Medicare's strength also reflects some order pull-forward ahead of the April 13 effective date for the new prior authorization requirements applying to PCDs billed under traditional Medicare fee-for-service. The key point is that underlying demand remains robust, and after the new prior authorization process settles down, we expect ordering patterns to normalize across quarters. Bear in mind that prior authorization for basic and advanced PCDs among Medicare patients was announced in January 2026, and it is consistent with prior authorization decisions in other growing DME categories. During our Q4 call, we discussed how we anticipated this new requirement would add further steps to the ordering workflow, such as assembling and submitting a prior authorization documentation packet and checking the status of each submission so the claim can be processed. Beyond that, under these new rules a patient has to have a face-to-face clinical visit with a treating physician—not just a therapist—to establish and document medical necessity. To get ready for the go-live date, we accelerated the prior authorization module in our AI portfolio, which we had originally planned to launch during 2027. In the weeks leading up to April 13, we demonstrated operational agility by validating the technology and systems, training and staffing our team, and getting a new process deployed successfully and on schedule. The Medicare PCD prior authorization mandate has been in place for just three weeks. We also expect roughly 22 million to 23 million shares. We're actively managing the early transition dynamics while both our company and the MACs refine their processes. As the industry leader and a DME provider with extensive experience operating under other prior authorization frameworks, including Medicare Advantage and commercial plans, we believe we're well positioned to assist patients through this transition. Now moving to our other payer channels, our commercial business remains healthy and consistent quarter over quarter. Regarding the VA channel, results reflect an operating and growth profile that's different from Medicare and commercial. While reimbursement policies in those channels are more fluid and have generated sharper year-over-year comparisons, the VA reimbursement landscape is considerably steadier, which naturally produces less quarter-to-quarter volatility. In terms of how we execute commercially, the VA's call points span a broad range of specialties — including vascular, oncology, and therapy practices — and outcomes there depend on consistent, relationship-driven engagement plus expertise in navigating local VA systems. Our field organization, which we recently expanded, continues to deepen its engagement, establishing workflows and building trusted relationships within these accounts, so we expect the VA to become a more significant contributor over time. We view the VA as a long-term strategic opportunity, one that aligns well with our evolving portfolio and adds incremental growth alongside our Medicare and commercial channels, with that growth coming in a deliberate, durable manner. Now turning to airway clearance. First quarter sales of AffloVest increased 22% versus the same period last year. The primary drivers behind this strong performance remain unchanged from what I've previously described. Relationships with the leading respiratory DMEs remain strong, C-suite included, and AffloVest continues to be favorably positioned across those accounts. Among our top 10 DME partners, there's opportunity for deeper engagement, given their extensive national footprints and the alignment between their individual branch performance goals and ours. Additionally, approximately 22 million to 23 million shares are relevant here.
Our focus is on providing top-tier medical education and training to providers and DME staff, backing the sales capabilities for AffloVest and airway clearance treatments during the DME national and area sales gatherings, producing a best-in-class airway clearance product, and ensuring AffloVest account manager continuity for our DME partners — all of which we see as essential ingredients for achieving steady growth and maintaining valued partner status. Being the market leader in airway clearance therapy, we stay dedicated to serving the millions of bronchiectasis patients in the U.S., both diagnosed and undiagnosed. We anticipate that our commercial approach, clinical education initiatives, and robust DME partnerships will keep fueling growth across the year, along with the introduction of our next-generation AffloVest product, which I'll discuss briefly. Our commitment to advancing our lymphedema strategy involves shifting from a product company to an integrated solutions leader for lymphatic dysfunction, and acquiring Lymphotech marks a key milestone in this thrilling progression. Lymphotech aligns perfectly with our strategy of supporting patients through the entire continuum of care, starting with obtaining an accurate, timely, and objective lymphedema diagnosis. Lymphotech's 3D measurement and monitoring directly fulfills this requirement, supplanting conventional manual measurement approaches that are time intensive, extremely inconsistent, and reliant on clinician skill. Right now, the Lymphotech platform holds FDA clearance and is commercially offered as a SaaS-based solution. As we mentioned last quarter, a crucial aspect of this acquisition is expanding our R&D strengths to enable next-generation methods for disease assessment and treatment, and we're eager to provide updates on our advancements in the coming quarters. Integration has been moving forward as anticipated since the February close. The Lymphotech cofounders and their team are actively involved in both the go-to-market commercialization strategy and in helping pinpoint capabilities and integration points throughout the diagnostic and therapy product development road maps. We're taking a deliberate and strategic approach to optimizing the provider, clinician, and patient experience. In addition to the team and technology, Lymphotech was also chosen as a funding recipient under a new federal research program dedicated to lymphatic disease. To be specific, the Advanced Research Projects Agency for Health recently unveiled two landmark programs, LIGHT and GUIDE, pledging a combined total exceeding $290 million to all awardees over five years to further lymphatic diagnosis and therapeutics. Lymphotech was picked as one of seven GUIDE funding recipients and is concentrating its research on creating a new responsive garment that uses bioimpedance feedback to provide adaptive compression with Bluetooth-enabled remote monitoring. We think this program could potentially bring personalized treatment to millions of diagnosed patients. Together with the first U.S. clinical practice guidelines for lower extremity lymphedema introduced in March, which validated PCD therapy, we believe awareness of lymphatic disease and evidence-supported therapies is hitting a historic inflection point for the category. As the industry leader, Tactile Systems Technology, Inc. occupies a strong spot right in the middle of that momentum, and our 3 continuing strategic priorities give it even more support: those center on making care easier to reach, widening the range of treatments available, and boosting the value we deliver from patients over their lifetimes. Now let me give you some updates on each one. Starting with making care easier to reach, an area where we're pursuing multiple efforts aimed both inside and outside the company. On the internal side, we keep reshaping every stage of the ordering journey through fresh technology infrastructure and smoother, more efficient workflows. AI-powered tools are becoming a more and more significant part of how we remake our back office. During the last few months, we've been applying AI tools within our order intake operations and in portions of our medical record review, and we've been happy with how the technology has performed as well as the workflow gains it's driving. As I mentioned before, during this quarter we managed to speed up and roll out the prior authorization piece of our AI platform for Medicare fee-for-service orders before the April 13 deadline arrived. Going forward, we expect to stay on schedule to broaden AI usage even further throughout the whole ordering journey, covering patient eligibility and benefits verification along with complete medical record review. Once these additional features are rolled out, we think we'll speed up the time to therapy, cut down on human mistakes that hurt revenue, and lift operational efficiency, and all of that ought to help margins widen as time goes on. On the external side, better market access conditions get support from generating clinical evidence, spreading guidelines, and talking with government as well as commercial payers; when it comes to commercial payers, we keep making consistent headway on head and neck coverage and are striving to bring certain commercial policies into line with the NCD instead of the way they currently line up with the retired LCD. As part of that effort, our head and neck clinical evidence program keeps moving forward, with data making its way through peer review and publication. Engaging payers is a commitment to patient advocacy we keep making on behalf of every patient, carried out through payer education, appealing denials, and bringing in clinical support from medical directors when necessary. Turning next to widening treatment options. We're happy to report that we just obtained FDA 510(k) clearance for the next generation of our AffloVest product. The main improvements in this next-generation device aim at bettering the patient experience, and they include additional weight reduction, new digital connectivity, and better size adjustability so the fit can be more customized. On top of that, the clearance keeps our indication for use spanning the entire patient age spectrum, from pediatrics all the way through geriatric populations, which strengthens AffloVest's standing as a bronchiectasis solution for patients at every stage of life. We're still on track to launch commercially this year so the product will be ready for the 2026 to 2027 winter respiratory season, and we look forward to providing more updates about timing as we get nearer. Our second innovation area targets the advanced pump category. As we told you last quarter, our product roadmap calls for adding incremental features and making product enhancements to Flexitouch that center on the patient experience. This covers a brand-new controller, less external tubing, and the ability to operate things remotely via our Kylie patient engagement app; for these capabilities, we expect readiness for market launch during 2027. Past those innovation developments, our attention is likewise on finding where integration can happen throughout the merged Lymphotech and Tactile product development portfolios. Though sharing specifics about a product portfolio integrated with Lymphotech would be premature, the growth of chances in diagnostics and therapy delivery has us enthusiastic. Last, boosting lifetime patient value—our third strategic priority—takes in engagement that is more efficient and personalized before, during, and after the order and delivery process. As discussed three months ago, we keep concentrating on targeted care navigation pilots meant to give patients clearer direction sooner in the process and cut down administrative friction. Findings so far keep backing our thesis that clear communication and guidance earlier in the process matter to patients. We are honing these pilots to optimize touchpoints, and we are assessing how to grow their impact in a way that is measured and scalable; our belief is that this effort will cut patient leakage, improve the patient experience, and eventually lower the need for sales representative involvement in the order process, bolstering both growth and operating leverage. Considered as a whole, our advancement on these strategic priorities strengthens our confidence in how durable our commercial momentum is.
Looking at what we delivered in Q1, you can see solid execution in both of our business lines, plus real momentum and nimbleness when it comes to the work we're doing to transform operations, along with the payoff we anticipated from what we've put into our go-to-market teams and technology. Being deliberate and staying disciplined are central to how we put our strategy into practice, and because of that, the performance shows up in the numbers. A healthy balance sheet backs this approach, along with a capital allocation plan that's carefully thought through and weighs growth spending against giving back to shareholders. We feel good about where this business is heading and about the many catalysts in front of us as 2026 unfolds and beyond. With that, I'll hand things to Elaine, who will walk through our Q1 financial results in greater detail and give you an update on what we expect for 2026.
Appreciate it, Sheri. Unless I note otherwise, all the first quarter financial figures I discuss are on a GAAP basis and compared with the prior year. Total revenue for Q1 climbed $14 million, or 23%, to hit $75.3 million. Breaking that down by product line: our lymphedema offerings — the Flexitouch, Entre, Nimble, and Lymphatex systems — saw sales and rentals increase $11.7 million, or 23%, landing at $62.2 million. On the airway clearance side, which includes the AffloVest system, sales were up $2.3 million, or 22%, totaling $13.0 million. Gains were spread broadly across the board, reflecting strength in both unit volume and revenue per unit, driven by higher shipment levels, solid collections, and a beneficial mix across payers and product categories. Continuing down the income statement, gross margin represented 76.5% of revenue, compared with 74% during 2025. Lower production costs, improved collections, and a favorable mix of products and payers as shown in our revenue primarily drove that gross margin gain. What matters is that these improvements stem from structural changes made to the business, not from short-term cost-cutting measures. First-quarter operating expenses climbed $9.3 million, which is 19%, reaching $59.1 million. The shift in GAAP operating expenses came from a $5.2 million rise in sales and marketing expenses, a $1.0 million rise in research and development expenses, and a $3.0 million rise in reimbursement, general, and administrative expenses. To revisit what we covered earlier, we're putting 2025's investments on an annualized basis while we keep funding IT infrastructure and automation so that we can grow over the long term. Despite those continuing outlays, our operating loss dropped by $3.0 million, which works out to 66%, landing at $1.5 million. Because our cash position is smaller, interest income came in at $700,000, a decrease of $200,000, or 26%. Interest expense was reduced by $400,000, or 93%, down to $28,000. On taxes, we recorded $900,000 of expense, versus a benefit of $1.1 million in the prior period. Net loss improved by $1.2 million, a 41% reduction, to $1.8 million, equal to $0.08 per diluted share, against $3.0 million, or $0.13 per diluted share. On an adjusted EBITDA basis, we reached $3.7 million, swinging from a loss of $300,000 during the same period last year. Margin went from negative 0.4% to 4.9%, which shows real gains in operating leverage. Looking at the balance sheet, we closed the quarter with $75 million in cash and cash equivalents, plus zero outstanding borrowings. At 12/31/2025, those figures stood at $83.4 million in cash with no outstanding borrowings. The quarter's cash movement is mostly tied to the Lymphotech acquisition, share repurchases, and typical seasonal items like bonus payments. Working capital keeps getting better, and days sales outstanding came down significantly. Now let's go over what we expect for 2026. Looking ahead to the whole of 2026, our forecast has been lifted, and we now anticipate total revenue landing somewhere between $360 million and $368 million — which works out to roughly 9% to 12% growth compared with the prior year. Built into this outlook is an assumption that both the lymphedema and airway clearance sides of our business will expand within a broadly similar range, though airway clearance should post somewhat quicker growth. Three main things are behind this bump to our guidance. First, we continue to count on solid commercial execution across the company. Second, we've included what Lymphotech contributes. And third, our early confidence is building around how the MACs are adapting to the new prior authorization requirements we discussed on our last call. Looking more broadly, we think underlying demand is staying durable, and our tools and processes built to assist with prior authorizations are performing well versus plans. Although prior authorization approval data remains early and is still developing, our outlook properly builds in discipline until we have a longer history of steady results. If you're building a model for the whole of 2026, here's what we're looking at: GAAP gross margins should land between 76% and 77%. GAAP operating expenses will be up 10% to 12% compared with a year earlier — that step-up relative to what we told you before comes from one-time costs tied to acquisitions and legal matters. Net interest income should come in around $3 million, the tax rate at 28%, and fully diluted weighted average shares outstanding at roughly 22 to 23 million. Adjusted EBITDA for 2026 is still projected at $49 million to $51 million. Wrapped into this view is the fact that 2025's investments are now annualizing, plus the strategic investments we keep making in 2026 — both of which we see as important to underpinning long-term growth and operating leverage. When we look at our adjusted EBITDA guidance, it factors in several noncash items. These include roughly $9 million for stock compensation, about $3.6 million in intangible amortization, approximately $3.2 million of depreciation, around $1 million tied to litigation, and $1.3 million in one-time costs from acquisitions and integration. Having said that, I'll turn things back over to Sheri, who has some final comments.
Thanks, Elaine. The year has gotten off to a solid, well-balanced beginning, and we're pleased with how the business is trending. Broad-based results in Q1 showed what disciplined execution can do, with productivity gains coming through now that our commercial organization is fully built out, plus growing returns on the money we've put into technology and infrastructure. Going forward, we're staying fixed on the fundamentals that count the most: widening access to care, driving innovation throughout our product portfolio, and lifting lifetime patient value. We're keeping an eye on the near-term adjustments tied to Medicare prior authorization, but in the end we see this shift strengthening our focus on clinical rigor, durable access, and stable reimbursement over the long haul, and we're positioned well to handle it. The strength we're operating from rests on a resilient balance sheet, several growth levers already in motion, and a clear strategy for turning consistent execution into sustained growth down the road. With that, operator, we'll open the call for questions now. If you'd like to take your question out of the queue, you can press 2. Once more, that's 1 to ask a question.
Good afternoon, and congratulations on a solid start to the year. I'd like to ask about some of the dynamics beginning to emerge in the second quarter. Sheri, I believe you mentioned some pull-forward dynamic with lymphedema sales ahead of February. So, first, if I look at the beat versus where you're raising guidance, it came in with roughly a $1.7 million difference there. I just want to understand whether that was the pull-forward effect, and then just anecdotally, what you're seeing with the MACs in February, how they're responding to this, how physicians are responding to this, and the cadence of sales we should think about. I apologize, there's a lot here. The cadence of sales we should think about over the balance of the year, because you have historically seen 2Q step up from 1Q. So is there a bit of a pause or dynamic in the market we need to think about for 2Q? Sorry for the multipart question there.
No, it's okay. Let's take it layer by layer here; so what I'll first say is I want to reorient this concept of a pull-forward, because it wasn't really a pull-forward. What we did is we had patients whose orders were in process, and if they weren't all the way completed by that date, they would have been exposed to an overall denial. And so what we did is a little bit of an acceleration of that, but I wouldn't characterize it as pulling orders, if you will, from Q2 and shipments from Q2 into Q1. What we've been doing and what we've been seeing truly is great on our side in terms of our systems and our processes are working; we're really pleased. We accelerated what we were going to do next year and got it all in place by that go-live date, so very pleased with that. So what you're seeing in terms of our positioning on the prior authorization doesn't have anything to do with our readiness. It really has to do with some early variability that we're seeing within the MACs, and, again, Ryan, we're only three weeks into this entire process, so it's still new. Orders are flowing through; we're seeing what those denial and approval rates are, but we're seeing some differences between the MACs. And so there shouldn't be variability between the MACs. If you're in one state, you're a Medicare patient, and you have the exact same criteria, you shouldn't be denied based on where you live. And so we're seeing a little bit of variability. You see this fairly often, since MACs want to confirm that everyone is reading things the same way — how the data and information flows on their end, plus training and education. So from our perspective, nothing we're observing looks like anything beyond administrative matters, and we'll get a chance to sit down with the MACs regarding it. Beyond that, we don't view any of this as something that will persist over time; we're confident we can make adjustments, and as we gain more experience with prior authorization, our confidence should grow around what the actual process time is, along with those approval rates. When it comes to guidance, we did include what the Lymphotech revenue would have been, as well as a portion of our broader confidence in business delivery, and then we'll hold back a bit until a few more weeks pass — not the entire year — until we begin to see how that prior auth process takes shape, once again more from the MACs' perspective than from ours.
Thanks, that's helpful feedback. Ryan, I believe the remaining item you raised had to do with how things are sequenced across the second and third quarters. Well, as has always been the case, our expectation continues to be that Q2 will show growth relative to Q1. That said, I'd note that this year, Q2 and Q3 are going to appear somewhat different, in my view. The combined result for those two periods will be equal, though I'd describe the increase in Q2 as somewhat smaller than what we've witnessed in earlier years, and likely a larger increase in Q3 as things begin to settle into a normal pattern. Right when that took hold, it introduced some lag, since the prior authorization opened the path for those replies and for this entirely new procedure to begin. So on the whole, the same total will come from the two quarters, yet a slight gap will exist between them.
All right, that is really useful. Now I will slip in one final one, then rejoin the queue, since by this point I have likely posed too many. Still, regarding what Lymphotech adds, I appreciate that you flagged it. First, at what point in the year do you anticipate that becoming significant? In other words, how ought we to model the moment it genuinely begins to taper off? Second, when we consider what it might accomplish across time, how are you viewing the potential contribution Lymphotech could make to the business as we peer ahead toward 2027 and past that? Thanks for taking the question.
Sure thing. Regarding Lymphotech, the grants we mentioned — we are extremely enthusiastic about the LIGHT grant along with the GUIDE grant — in fact arrive as revenue, and that is the reason it now sits within the total guidance we provided; yet before that point, at the time of our initial guidance, we anticipated no meaningful expansion stemming from Lymphotech and no substantial contribution. Therefore, what you observe at present truly stems from the grant arriving as revenue. The area where our enthusiasm for Lymphotech runs highest will not significantly affect this year. What I mean is, we pursued the acquisition across several dimensions, yet the capacity plus the R&D strengths Lymphotech delivers are going to form a major element of how we approach our path ahead, not merely as a next generation Flexitouch, but when you consider therapy broadly; and once you examine the specifics — as I laid out the specifics of that GUIDE — really studying garments employing bioimpedance and providing personalized care, that has us quite excited. Right now I simply am unable to disclose any timelines regarding the shape of that R&D portfolio, though we will manage to reveal far more in the quarters ahead once it becomes better established within our wider strategy for therapy delivery; over on the diagnostic side, a major catalyst we recognize for Lymphotech is in fact securing the FDA approval for additional diagnostic indication and afterward clearing the CPT codes that genuinely allow payment for the diagnostic. So that will require a bit of time, yet in the present moment, we are extremely enthusiastic that the federally funded government grants are assisting the R&D work that we know will slot straight into our portfolio down the road. Hey, Ryan, one final point — your question was excellent, but I would sort of like to bracket it concerning the guidance and the flow through. Once more, as we stated, it has only been three weeks in. When the switch happened from the LCD over to the NCD, we observed it and we kept our position, since we understood interpretation shifts were coming, plus we'd need time to make progress before feeling really sure about how we could push into that. So all of our current efforts rest on precedent and our prior experience, which turned out successfully. We have confidence that those administrative components during the early phase of prior auth will move along smoothly, and nobody is better situated to manage that. So yes, it's a genuine issue, yet we aren't sitting here overly worried. We simply need additional time so we can completely spell out what that benefit looks like. That's the question nobody posed, but given the ones that were posed, I wanted to close things out with it.
Thank you.
Yep. Thanks.
Congratulations on a solid quarter. I really don't want to bring this up, but could we pause briefly on the idea of pull-forward compared with accelerated? I'm not certain I completely grasp it, and I'd like to ensure it's clear, since I believe it will matter for understanding, first, how strong the quarter was and, second, the sequential shifts going forward. So perhaps take a moment to focus specifically on the distinctions behind why a pull-forward is — or rather — why accelerated sales don't necessarily represent sales pulled forward out of Q2?
The reason we accelerated orders was to benefit patients, not to make up for revenue. Usually, a pull-forward happens when you're attempting to compensate for revenue — you're trying to speed up what you'd otherwise have gotten as revenue in the following quarter and shift it into the current one. When we refer to order acceleration, we genuinely did it to benefit patients. Any of those patients who had an order in progress, had they not gotten that order cleared by the April 13 date, would have needed it to go entirely back and be resubmitted for a prior auth. So there were certain orders we had — this isn't a material amount — that were set to land on April 13; we dedicated additional resources to help ensure that order was completed, yet we weren't pulling an order out of Q2 in order to record the revenue in Q1.
All right, understood. That makes sense. Thanks. Perhaps a question that follows on from this, taking a somewhat wider view. You have a great deal of commercial spending that has been carried through 2025 and is now accelerating as we enter this year. Could you perhaps describe how developed some of these are? Should those advantages keep expanding? Have some of them, such as the commercial team and similar areas, reached maturity? So perhaps just tell us which stage we have reached with a few of these more significant commercial investments. Thank you.
Absolutely. Regarding our headcount, we are genuinely happy with the position we are in at present, and as I mentioned during the prepared remarks, we are shifting away from building capacity and onboarding toward genuine productivity. Our sales organization is now fully resourced, with our territory managers and account specialists standing at a one-to-one ratio, so we believe we are in a very strong position. When it comes to our CRM tool, our reps keep using it, including the workflow tools that do a great deal to assist their activities — that too is proceeding very well — and we anticipate that revenue per rep year-on-year growth will become positive as the year moves forward. Ultimately, we are definitely moving away from building and introducing the tool toward possessing a fully resourced field organization that is advancing and keeps advancing; we are witnessing a rise in overall referrals per rep and believe we are in a very strong position with that.
Yes, hello, Kyle here covering for Adam. Thank you for taking my questions, and congratulations on a solid beginning to the year. Perhaps I'll ask about the EBITDA guidance. The Q1 result came in above expectations, and then you lifted revenue guidance. So I'm just trying to help understand — or maybe you could help us unpack — why the EBITDA guidance stays roughly where it is. I know you referenced certain acquisition costs and certain one-time expenses there, and I picked up on the increase in OpEx spend for the year. Should we read a lot of that as kind of tied to this acquisition, or is it more about this strong R&D pipeline? Could you just help us a bit there?
On that point, I think there are likely two factors. One is that part of the increase stems from Lymphotech. As Sheri mentioned, that is really tied to the grant work we are doing, where it is really service-based work that sits on the lower-margin side. Again, this is not the broader business model, but happens to be in our revenue this year. And so that is one of the reasons why. Then second, as you said, we did have some in-period one-time costs in our OpEx as well; but I would say the biggest driver is really just the type of revenue lift that is coming from Lymphotech and the nature of that revenue.
All right, understood. That's useful. And congratulations on getting the clearance for the next-gen AffloVest — I realize that was a big milestone to get through. I wanted to follow up on that point in particular. From what you're saying, it sounds like you'll be able to launch this for this winter season, as you mentioned. How should we frame that when it comes to growth from that product — from the next-gen system with the advanced features? And is much of that reflected in the guidance for the full year, perhaps only a small amount near the end of the year? Is it basically just an upside lever right now?
Yes, thank you for asking, and we're extremely thrilled to have received the FDA approval for this product and truly excited about these features that will help enhance that patient experience. As a quick reminder, reimbursement is identical for our current generation and for the next-generation AffloVest, so no additional reimbursement exists for it, and it certainly will be available; right now we're working with our DMEs on the timing so they can wind down the inventory they currently hold on the Gen 5 and so that training and education are complete in time for that respiratory season at the end of this year and going into next year. From the standpoint of overall guidance, our guidance assumes both lymphedema and airway clearance will grow in a comparable overall range, with airway clearance growing a bit faster, and that's already reflected in our guide. We expected to have the product this year and, once again, with no incremental dollars out there on the reimbursement side. It's simply a better patient experience, and we'll keep driving penetration and adoption within our DMEs.
Good afternoon, and thank you for taking my questions. To start, I was hoping you could give us a bit more detail on the lower limb guidelines — what has the early feedback from clinicians looked like? Also, could you offer some general thoughts on how the lymphedema market breaks down by mix — is it true that 52% of cases involve the lower limb? Any insight along those lines would be useful for investors.
Of course. Regarding the guidelines, we're very happy that they were presented at AVS in February, and we expect publication to happen this summer. Naturally, having those guidelines is a positive thing. When it comes to getting the word out about them and training physicians, our teams are ready to support that effort and assist with the broader education. We're especially glad that pneumatic compression devices were explicitly named as part of guideline-based care, since that sets them apart from products that aren't PCDs. So it's exciting that we're well positioned within the overall evidence-based care guidelines, and we'll take that forward and help spread the message.
Now, regarding how the cases break down between arms and legs, the most useful framing is really to look at what brings on lymphedema in the first place. Roughly 1 in 3 patients, as we've noted, develop lymphedema because of cancer, and the rest have various other causes, with CVI standing out as a major one. When cancer is the culprit, it's frequently the upper body — think breast cancer, head and neck cancer. Pelvic cancers of any kind can still involve the lower extremities somewhat, yet upper extremity is what you generally encounter there, whereas the other triggers, usually CVI, tend to show up in the lower extremities; so that should give you some rough picture, though the real determinant is the underlying cause or driver, since that's what dictates which part of the body the lymphedema affects.
That is certainly useful. Also, should we anticipate more clinical guidelines coming out soon covering upper extremities, or other upper regions of the body?
As Elaine mentioned, there absolutely are, and much of that sits within oncology. So some white papers are indeed focused there, and that could certainly come to pass. I do not know of anything particular currently underway regarding the upper extremity side, but we are quite happy with how strongly positioned and widely adopted pneumatic compression therapy is among upper extremity patients, especially with therapists, and in oncology it is clearly understood, while lymphedema in the lower extremity can be nearly a matter of elimination. For sure, when patients have cancer, you know a lymph node has been removed, or you know something has been done to the lymphatic system in a surgical procedure — unlike the lower extremity; so we typically observe that within oncology, and among lymphedema therapists there is greater comprehension of the lymphatic disruption caused by the specific oncology intervention. So guidelines might be of value, but there is not the same degree of disconnect that we have observed in the lower extremity.
So when you look at the numbers, not only do you have additional patients, but you also have lower penetration, so to speak, within that population. So in theory, that's sort of a double whammy for you folks.
Your statement is correct.
My view is that the lower extremity represents the bigger group. What Sheri is pointing out, I believe, is that for that group the guidelines carry greater significance, since no clear cause of the lymphatic disruption exists, meaning these guidelines genuinely assist in finding it sooner. In contrast, with the upper extremity a clear cause does exist, so both patients and clinicians tend to be on the lookout for it even without guidelines.
All right. Sounds like we're aligned on that. Great. Then just one final thing from my side, if I may squeeze it in. Can you share anything regarding that new bronchiectasis drug on the market? Have you noticed any meaningful effect when it comes to airway clearance?
Of course. It's been our position — and our belief — that when a pharmaceutical product arrives that's designed specifically for bronchiectasis patients, it boosts recognition of the wider category, so we've seen a pleasant lift for the category overall. When it comes to airway clearance, however — what they refer to as the vicious vortex — the problems are inflammation, then mucus, then infection. That drug does help with inflammation, yet inflammation represents merely a single piece of the entire vicious vortex tied to bronchiectasis. Inflammation will still be there, and where there's inflammation, mucus will still be there, and where there's mucus, there will still be chances for infection. That means the need to genuinely clear the airway remains highly relevant for this group of patients. That's the feedback we get from our clinicians, and the way the product is positioned isn't that it takes the place of airway clearance; rather, it works alongside — it can be used alongside and adjacent to it — but it isn't a case of one against the other. We're glad it's boosting awareness and building education surrounding the disease of bronchiectasis, yet we aren't observing any shift in the actual care pathway for these patients; it's simply another choice to be used alongside an airway clearance product.
That's clear. I appreciate you fielding the questions, and nice work on the quarter.
Appreciate it. And to everyone joining us, thanks for being part of the call. That brings today’s teleconference to a close. Feel free to drop off your lines, and enjoy the rest of your day. Thanks so much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tactile Systems Technology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Tactile Systems Technology, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.